ASN011

ASN011 is an investigational small‑molecule cytokine signaling pathway inhibitor originally developed by Asana BioSciences for autoimmune and inflammatory skin diseases, particularly atopic dermatitis and broader autoimmune disorders.[7][9] It is described as a preclinical, dual JAK/SYK‑pathway–related cytokine inhibitor asset within Asana’s immunology portfolio and was later included in a portfolio of immunodermatology assets acquired by TrialSpark and placed into the Libertas Bio pipeline.[1][9][11] Development reached the preclinical stage in immune system and autoimmune disease indications before the program was discontinued, and no clinical data, specific molecular target, or structural class beyond “cytokine pathway inhibitor” and “small molecule” have been publicly disclosed.[1][7][9]